电脑桌面
添加小米粒文库到电脑桌面
安装后可以在桌面快捷访问

美国cGMP-中英文对照

美国cGMP-中英文对照_第1页
1/49
美国cGMP-中英文对照_第2页
2/49
美国cGMP-中英文对照_第3页
3/49
PART 210 CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL210 部分 有关于生产、加工、包装和药品的储存的现行 GMP;一般准则Sec 。 210.1 Status of current good manufacturing practice regulations.210.1 cGMP 的法规地位。(a) The regulations set forth in this part and in parts 211 through 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety , and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.(a)在本部分及本章第 211-226 部分中所陈述的法规,为现行 GMP 最低要求,适用于药品制造、加工、包装或贮存中所采纳的方法及所使用的设施或控制手段,以保证该药品符合《联邦食品、药品及化妆品法案》(以下简称法案)对安全性的要求,具有均一性和效价(或含量)并符合或代表其生产过程的质量及纯度等特征。(b) The failure to comply with any regulation set forth in this part and in parts 211 through 226 of this chapter in the manufacture , processing, packing , or holding of a drug shall render such drug to be adulterated under section 501(a) (2)(B) of the act and such drug, as well as the person who is responsible for the failure to comply , shall be subject to regulatory action。(b)凡是在药品生产、加工、包装或贮存过程中存在任何不符合本部分及 21CFR 211-226部分中陈述的法规的药品,依据联邦食品、药品及化妆品法 501 (a)(2)—(B),该药应被视为劣药,同时导致该事故发生的负责人应受相应的法规的制裁。(c) Owners and operators of establishments engaged in the recovery, donor screening , testing (including donor testing), processing, storage ...

1、当您付费下载文档后,您只拥有了使用权限,并不意味着购买了版权,文档只能用于自身使用,不得用于其他商业用途(如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利)。
2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。
3、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。

碎片内容

美国cGMP-中英文对照

确认删除?
VIP
微信客服
  • 扫码咨询
会员Q群
  • 会员专属群点击这里加入QQ群
客服邮箱
回到顶部